Empagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), is a novel diabetic medication that reduces the risk of progression of chronic kidney dise…

Non-diabetic Chronic Kidney Disease

~Estimated

~$10 – $5,625

VA Office of Research and DevelopmentNCT07060417

Phase 1

The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery

The goal of this study is to understand the role of glucagon signal on glucose metabolism in individuals with and without bariatric surgery. The study is invol…

Non-Diabetic

~Estimated

~$10 – $6,250

The University of Texas Health Science Center at San AntonioNCT07212868

Phase 1

A Phase 1, Double-Blind, Randomized, Ascending-Dose, Placebo-Controlled, Multiple-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets Orally Administered in Non-diabetic Overweight or Obese Adult Subjects

This is a Phase 1, single-center, randomized, placebo-controlled, ascending dose study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD)…

Non-diabetic Overweight or Obese

~Estimated

~$10 – $8,750

BrightGene Bio-Medical Technology Co., Ltd.NCT07166081